EML4 (EMAP like 4)

symbol:
EML4
locus group:
protein-coding gene
location:
2p21
gene_family:
WD repeat domain containing
alias symbol:
ROPP120|ELP120
alias name:
None
entrez id:
27436
ensembl gene id:
ENSG00000143924
ucsc gene id:
uc002rsi.3
refseq accession:
NM_019063
hgnc_id:
HGNC:1316
approved reserved:
2000-01-31
2p21

EML4(Echinoderm Microtubule-Associated Protein-Like 4)是一种微管相关蛋白,属于EML基因家族,该家族成员通常参与微管动力学调控和细胞骨架的稳定。EML4基因编码的蛋白含有WD40重复结构域(一种常见的蛋白相互作用模块)和疏水棘皮动物微管结合结构域(HEAT repeats),这些结构使其能够结合微管并参与有丝分裂、细胞形态维持及细胞内运输等过程。EML4在多种组织中表达,尤其在脑和睾丸中表达较高。EML4基因的突变或异常融合可能破坏其功能,例如EML4-ALK融合基因(由EML4与间变性淋巴瘤激酶ALK基因融合形成)是非小细胞肺癌(NSCLC)中常见的致癌驱动突变,这种融合导致ALK激酶持续激活,促进细胞增殖和肿瘤发展。EML4过表达可能干扰微管功能,影响细胞分裂,导致基因组不稳定性;而表达降低可能削弱微管稳定性,影响神经元或精子细胞的正常功能。EML基因家族的共性包括参与微管组织、细胞周期调控及信号转导,其成员通常通过WD40或HEAT结构域与其他蛋白或微管相互作用。除癌症外,EML4的异常表达还与神经退行性疾病和生殖功能障碍相关,例如微管功能紊乱可能导致神经元轴突运输障碍。研究EML4有助于开发靶向药物,如针对EML4-ALK融合的抑制剂(如克唑替尼)已用于肺癌治疗。

中文English

此基因是棘皮动物微管相关蛋白样家族的一个成员。经编码的WD重复蛋白质可能参与了微管的形成。该基因与间变性淋巴瘤受体酪氨酸激酶基因,其产生EML4-ALK融合转录物,是与非小细胞肺癌相关联的主要的突变中的一个部分的部件的异常融合。两个转录物变体该基因的结果的选择性剪接。 [由RefSeq的,2015年1月提供]

EML4基因的碱基序列:[NCBI]
Loading Gene Browser...
蛋白质序列
1MDGFAGSLDD SISAASTSDV QDRLSALESR VQQQEDEITV
41LKAALADVLR RLAISEDHVA SVKKSVSSKG QPSPRAVIPM
81 SCITNGSGA NRKPSHTSAV SIAGKETLSS AAKSGTEKKK
121EKPQGQREKK EESHSNDQSP QIRASPSPQP SSQPLQIHRQ
161T PESKNATP TKSIKRPSPA EKSHNSWENS DDSRNKLSKI
201PSTPKLIPKV TKTADKHKDV IINQEGEYIK MFMRGRPITM
241FI PSDVDNY DDIRTELPPE KLKLEWAYGY RGKDCRANVY
281LLPTGKIVYF IASVVVLFNY EERTQRHYLG HTDCVKCLAI
321HPD KIRIAT GQIAGVDKDG RPLQPHVRVW DSVTLSTLQI
361IGLGTFERGV GCLDFSKADS GVHLCIIDDS NEHMLTVWDW
401QKKA KGAEI KTTNEVVLAV EFHPTDANTI ITCGKSHIFF
441WTWSGNSLTR KQGIFGKYEK PKFVQCLAFL GNGDVLTGDS
481GGVML IWSK TTVEPTPGKG PKGVYQISKQ IKAHDGSVFT
521LCQMRNGMLL TGGGKDRKII LWDHDLNPER EIEVPDQYGT
561IRAVAE GKA DQFLVGTSRN FILRGTFNDG FQIEVQGHTD
601ELWGLATHPF KDLLLTCAQD RQVCLWNSME HRLEWTRLVD
641EPGHCAD FH PSGTVVAIGT HSGRWFVLDA ETRDLVSIHT
681DGNEQLSVMR YSIDGTFLAV GSHDNFIYLY VVSENGRKYS
721RYGRCTGH S SYITHLDWSP DNKYIMSNSG DYEILYWDIP
761NGCKLIRNRS DCKDIDWTTY TCVLGFQVFG VWPEGSDGTD
801INALVRSHN RKVIAVADDF CKVHLFQYPC SKAKAPSHKY
841SAHSSHVTNV SFTHNDSHLI STGGKDMSII QWKLVEKLSL
881PQNETVADTT LTKAPVSST ESVIQSNTPT PPPSQPLNET
921AEEESRISSS PTLLENSLEQ TVEPSEDHSE EESEEGSGDL
961GEPLYEEPCN E ISKEQAKA TLLEDQQDPS PSS
结构预测来自 AlphaFold DB(UniProt: Q9HC35),颜色表示 pLDDT 置信度(深蓝高、黄橙低)。
EML4基因的碱基突变:           仅显示部分snp
rs4048       rs7233       rs13375       rs744916       rs997288       rs997289       rs1017466       rs1017467       rs1044562       rs1127946       rs1134696       rs1134697       rs1371196       rs1371197       rs1439225       rs1439226       rs1439227      

EML4基因在不同组织中的表达:    [UniProt]

基因在不同组织中的表达图
正向引物序列
正向Tm值
反向引物序列
反向Tm值
评分
GTGGACAGATGATAGTATTTCTGC
60
GTTGCTGAACTCGTGACTC
59
CCGATGTTGACAACTATGATGAC
60
TCCTCGATAACCATATGCCC
59
CCGATGTTGACAACTATGATGAC
60
TCCTCGATAACCATATGCCC
59
CTGGAGGAGGGAAAGACAG
59
ACTGATCAGGAACCTCTATTTCTC
60
ATCCACACTGCAGATTATTGG
59
AATGAACACCTGAATCTGCT
58
CCGATGTTGACAACTATGATGAC
60
TCCTCGATAACCATATGCCC
59
TGGATAAAGATGGAAGGCCTC
60
GTCCAATAATCTGCAGTGTGG
59
AATCAGTCTCAAGTAAAGGCCA
60
TCTGTTTGCACCACTTCCA
60
GGAAGGTGCACTCTTTCAG
59
CAGCAGAGACAGTGTTGAC
59
TCCACACTGCAGATTATTGG
58
AATGAACACCTGAATCTGCT
58
      尚未收录相关数据

EML4基因(以及对应的蛋白质)的细胞分布位置:

[UniProt]     [GenomeNet]

" d="M482.414,245.296c3.539,4.293,4.455,10.009,0.202,11 c-4.244,0.996-4.983-10.983-8.293-8.438c-5.271,4.08,9.834,12.271,5.144,17.287c-3.717,3.607-6.172-5.75-10.839-1.976 c-4.673,3.776,6.781,7.299,2.831,11.326c-4.354,4.045-6.979-1.449-9.837-5.517c-1.193-1.742-2.059-3.851-3.595-2.748 c-1.516,1.078-1.854,1.795-0.938,3.666c2.374,4.854,9.235,10.119,5.156,12.535c-5.636,3.346-5.044-8.871-9.426-7.574 c-4.388,1.291,2.557,10.66-1.245,11.141c-4.089,0.545-3.483-10.239-6.979-8.575c-2.522,1.206-0.929,3.071-0.938,4.899 c0.004,1.32-0.964,3.6-2.372,4.062c-3.593,1.171-8.544-1.065-10.251-3.59c-6.04-8.93,0.396-15.997,4.639-7.015 c3.023,4.642,5.182,0.834,2.839-2.219c-1.032-1.354-4.309-5.901-0.781-7.252c2.904-1.113,4.271,1.941,5.985,4.592 c2.61,4.016,5.485,0.117,3.031-3.414c-1.828-2.633-2.74-3.803,3.156-7.42c6.405-4.369,6.52,3.869,10.077,0.646 c2.309-1.832-4.783-5.149,0.06-8.995c2.896-2.293,5.18,6.207,7.961,3.516c3.523-2.737-7.717-7.369,0.117-11.736 C473.413,240.77,480.519,242.891,482.414,245.296z"/> Extracellular space Cytosol Plasma membrane Cytoskeleton Lysosome Endosome Peroxisome ER Golgi Apparatus Nucleus Mitochondrion 0 1 2 3 4 5 Confidence
  • 质膜
  • 细胞质
  • 细胞外
  • 高尔基体
  • 囊泡
  • 细胞骨架
  • 内质网
  • 细胞核
  • 内体
  • 溶酶体
  • 线粒体

EML4基因的本体(GO)信息:

GO库代码
对应的蛋白质
来源代码
GO:0003674
Q9HC35 (UniProtKB)
ND
GO:0005737
Q9HC35 (UniProtKB)
NAS
GO:0005874
Q9HC35 (UniProtKB)
IEA
GO:0007017
Q9HC35 (UniProtKB)
NAS
GO:0007067
Q9HC35 (UniProtKB)
NAS
GO:0016020
Q9HC35 (UniProtKB)
IDA

可能调控 EML4基因的相关microRNA:     

String
BioGrid
IntAct
mentha
加载中…
关联基因 作用方式 资源库来源/分值
疾病名称 关系值 NofPmids NofSnps 来源
疾病名称 关系值 NofPmids NofSnps 来源
Non-Small Cell Lung Carcinoma 0.144429768 91 0 BeFree_CTD_human
Adenocarcinoma of lung (disorder) 0.123257302 13 0 BeFree_CTD_human
Neoplasm Metastasis 0.120271442 3 0 BeFree_CTD_human
Brain Neoplasms 0.12 1 0 CTD_human
Lung Neoplasms 0.016531667 8 0 BeFree_GAD_LHGDN
Adenocarcinoma 0.009695963 27 0 BeFree_GAD
Malignant neoplasm of lung 0.007600372 28 0 BeFree
Carcinoma of lung 0.004614512 17 0 BeFree
Squamous cell carcinoma 0.001357209 5 0 BeFree
Anaplastic large B-cell lymphoma 0.001085767 4 0 BeFree
Retrospective study of alectinib treatment among variants of ALK fusion in lung adenocarcinoma.
Watanabe Y, Takigami A, Hisata S, Nakayama M, Mato N, Maemondo M Transl Lung Cancer Res IF: 3.4 2026-03-23
Short-term response to alectinib and rapid progression in a lung squamous cell carcinoma patient harboring an EML4-ALK fusion: a case report.
Li S, Du X, Zhang X, Ma H, Yang Y, Li Y, Wei Q, Chen Y, Li H, Bu P, Liu D, Han S, Chen D Transl Cancer Res IF: 2.1 2026-03-31
The Extended Spectrum of Morphologic and Molecular Findings in ALK Fusion Spitz Neoplasms : A Study of 144 Cases.
Holic LJ, Trichy NS, Braat J, Olivares S, Florell S, Ko J, Busam KJ, Gerami P Am J Surg Pathol IF: 4.2 2026-06-01
A rare pulmonary epithelioid angiosarcoma with ALK rearrangement: a case report and literature review.
Gong J, Zheng L, Tian F, Xiao P, Yu D, Jiang L, Bao P Front Oncol IF: 3.4 None
Differences Among Genomic Profiling Tests for Bone and Soft-Tissue Sarcomas in a Universal Health Insurance System.
Kamio S, Ikegami M, Kitada R, Miwa S, Ogura K, Iwata S, Kawai A, Kobayashi E, Suehara Y, Kohsaka S J Bone Joint Surg Am IF: 4.5 2026-05-27
High Programmed Death-Ligand 1 Expression is Associated With a Shorter Progression Free Survival in ALK-Rearranged Lung Cancer Patients Treated With First Line Tyrosine Kinase Inhibitors.
Nie Y, Staley A, Hinz TK, Perez-Johnston R, Merrick DT, Yang MC, Davies KD, Bunn PA, Aisner DL, Camidge DR, Schenk EL, Heasley LE, Patil T Clin Lung Cancer IF: 3.9 2026-06-00
De Novo Actionable Genomic Alterations in High-Grade Pulmonary Neuroendocrine Carcinomas: Therapeutic Implications of Targeted Treatment.
Raphael A, Peled N, Gillis R, Nechushtan H, Shalata W, Dudnik E Med Sci (Basel) 2026-08-18

评论加载中...

登录后即可发表评论 登录 注册

联系地址

山东省济南市章丘区文博路2号

齐鲁师范学院 genelibs生信实验室

山东省济南市高新区舜华路750号

大学科技园北区F座4单元2楼

电话: 0531-88819269

微信公众号

关注微信订阅号,实时查看信息,关注医学生物学动态。


商务邮箱

E-mail: product@genelibs.com